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Abstract: The therapeutic potential of natural bioactive compounds such as polysaccharides, 
especially glycosaminoglycans, is now well documented, and this activity combined with 
natural biodiversity will allow the development of a new generation of therapeutics. 
Advances in our understanding of the biosynthesis, structure and function of complex 
glycans from mammalian origin have shown the crucial role of this class of molecules to 
modulate disease processes and the importance of a deeper knowledge of structure-activity 
relationships. Marine environment offers a tremendous biodiversity and original 
polysaccharides have been discovered presenting a great chemical diversity that is largely 
species specific. The study of the biological properties of the polysaccharides from   
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marine eukaryotes and marine prokaryotes revealed that the polysaccharides from   
the marine environment could provide a valid alternative to traditional polysaccharides 
such as glycosaminoglycans. Marine polysaccharides present a real potential for   
natural product drug discovery and for the delivery of new marine derived products for 
therapeutic applications. 
Keywords: marine bacteria; marine algae; exopolysaccharides; sulfated polysaccharides; 
structure; chemical modification; biological activity; blue biotechnology; cell therapy; 
tissue engineering 
 
1. Introduction 
Sulfated polysaccharides have diverse functions in the tissues from which they originate. They are 
capable of binding with proteins at several levels of specificity and are involved mainly in the 
development, cell differentiation, cell adhesion, cell signaling and cell matrix interactions. These 
bioactive molecules present a great potential for medical, pharmaceutical and biotechnological 
applications such as wound dressings, biomaterials, tissue regeneration and 3D culture scaffolds and 
even drugs. The most studied for their biological properties are mammalian sulfated polysaccharides or 
glycoconjugates constituted by glycosaminoglycans (GAGs) composed of negatively charged osidic 
chains, most of them covalently linked to proteins. The discovery of the biological importance of the 
mammalian glycoconjugates has been the beginning of a new modern research field focusing on the 
carbohydrate based recognition phenomena, glycobiology [1,2]. It has been demonstrated that these 
particular biological properties were due to the chemical diversity of the osidic chains in which the 
patterns of sulfate substitution can give specific biological functions. It was also noted that the 
chemical diversity of the sulfated polysaccharides was largely species specific [3].  
Marine polysaccharides present an enormous variety of structures; they are still under-exploited and 
they should therefore be considered as an extraordinary source of chemical diversity for drug 
discovery [4]. Sulfated polysaccharides, possessing GAG-like biological properties, can be found 
either in marine eukaryotes or in marine prokaryotes. This marine origin should offer potentially safer 
compounds than mammalian polysaccharides for drug discovery. In this review, we will present first 
the biological properties of GAGs from mammalian origin in relation to cell therapy and tissue 
engineering. Then we will describe different studies made on marine polysaccharides,   
showing that these polysaccharides could advantageously replace mammalian GAGs in some   
therapeutic applications. 
2. Glycosaminoglycans: Structural Features, Biological Properties and Limitations for 
Therapeutic Use 
Glycosaminoglycans (GAGs) are present in all animals; some of them such as heparin and   
dermatan-sulfate are extracted from mammalian mucosa for therapeutical uses. GAGs can be located 
in the extracellular matrix, on the cell surface or within the intracellular compartment. These Mar. Drugs 2011, 9  
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polysaccharides are composed of disaccharide repeating units including one uronic acid (or neutral 
sugar for one of them) and one amino sugar. GAGs can be sulfated (chondroitin-sulfate,  
dermatan-sulfate, heparin/heparan-sulfate, keratan-sulfate) or not (hyaluronic acid). Furthermore, 
sulfated glycosaminoglycans can be covalently bound to a protein to form proteoglycans. Hyaluronic 
acid (HA) is very peculiar because it is neither sulfated, nor covalently linked to a protein to form 
proteoglycan. Moreover this polysaccharide has a very high molecular weight (up to 8 × 10
6 g/mol in 
tissue) in contrast to sulfated GAGs (from 10 to 100 × 10
3 g/mol) [5,6]. GAGs interact with a wide 
range of proteins involved in physiological and pathological processes. They display many biological 
activities which can influence tissue repair as well as inflammatory response [1,7–9].  
For example, heparan-sulfate chains borne by the cell surface proteoglycans are required to   
mediate signals of heparin-binding growth factors such as fibroblast growth factors (FGFs), heparin 
binding-epidermal growth factor (HB-EGF) or vascular endothelial growth factor (VEGF)   
(Figure 1) [10–12]. Furthermore in extracellular matrix, sulfated glycosaminoglycans are specifically 
involved in growth factor bioavailability and protection against proteinase degradation [13,14].   
Their ability to structure matrix macromolecules has been described on collagens as well as on matrix 
glycoproteins or elastic fibers [15–17]. Other studies demonstrated that heparin and chondroitin-sulfate 
directly inhibit serine-proteinase activity and modulate matrix metalloproteinase activity in cell   
culture [18,19]. Due to specific interactions with chemokines and selectins, heparan-sulfates found on 
endothelial cell surface are also major actors in leukocyte rolling and chemo-attraction [20,21]. 
Figure 1. Cell surface GAGs and cell behavior. (a) GAGs and cell adhesion; (b) GAGs 
and growth factor promotion.  
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Figure 1. Cont. 
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(b) 
The HA, a non-sulfated GAG, is also a major actor in tissue structuring and remodeling.   
The hallmark of this polysaccharide is its ability to form hydrogels allowing joint lubrication and  
space creation to cell migration during wound healing and embryonic morphogenesis [22]. During 
cutaneous wound healing, HA prevents fibrosis [23]. Thus, during fetal skin repair, which is 
characterized by scarless wound healing, high amounts of HA are produced whereas a dramatic 
downregulation of this GAG synthesis is observed in the keloids [24]. HA stimulates endothelial cell 
proliferation, migration and differentiation following activation of specific cell receptors (CD44 
receptor and hyaluronan-mediated motility receptor or RHAMM). HA is also involved in 
inflammatory response after injury by stimulation of macrophage cytokine secretion through CD44 
signaling pathway [21]. 
Thus, these polysaccharides could be advantageously proposed as pharmacological agents or 
biomaterials for tissue repair and engineering. Unfortunately, the strong anti-coagulant activity of 
some of them (heparin, heparan-sulfate), their animal origin increasing the risk for the presence of 
infectious agents such as viruses or prions, and an unreliable availability (cost, volume) restrict their 
use in Human. Marine organisms such as macroalgae, microalgae, bacteria, cyanobacteria, invertebrates 
and chordata offer a rich source of carbohydrates with original structures largely species specific. 
3. GAG-Like Polysaccharides from Marine Eukaryotes 
3.1. GAGs  
Hyaluronic acid, chondroitin sulfate, dermatan sulfate and heparan sulfate can be found in marine 
invertebrates; they have been isolated from marine mollusks or echinoderms such as sea urchins or sea 
cucumbers (ascidians). GAGs can be extracted from marine mollusk such as Amussium pleuronectus 
(Linne). The structural characterization showed that they are sulfated like heparin and contain Mar. Drugs 2011, 9  
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equivalent amount of uronic acid and hexosamine. They could be an alternative source of heparin [25]. 
The dermatan sulfates isolated from sea urchin and chondroitin sulfates from ascidians have the same 
backbone structures as the mammalian GAGs but possess different sulfation patterns [26,27]. In animal 
models, the fucosylated chondroitin sulfate obtained from sea cucumber was a promising molecule with 
possible beneficial effects in pathological conditions such as thrombosis and ischemia [27]. 
Chondroitin/dermatan sulfate hybrid chains extracted from shark skin showed a high affinity for 
growth factors and neurotrophic factors [28]. 
3.2. Alginate 
Marine alginate is found in all brown seaweeds (Phaeophyceae) in a proportion of 18 to 40% of the 
total plant. Alginate is both a biopolymer and a polyelectrolyte and is considered to be biocompatible, 
non-toxic, non-immmunogenic and biodegradable. Alginate is a high-molecular weight (in the   
range 200–500 × 10
3 g/mol) polyuronic acid composed of two types of uronic acid distributed as 
blocks of guluronic acid (GulA or “G”) or mannuronic acid (ManA or “M”) as well as heteropolymeric 
mixed sequences (GulA-ManA, usually alternating). Often commercial alginate is characterized by its 
“M:G” ratio. The alginate is known to form a physical gel by hydrogen bonding at low pH (acid gel) 
and by ionic interactions with divalent or trivalent ions, which act as crosslinkers between adjacent 
polymer chains. The alginate and alginate with chemical modifications on carboxyl or hydroxyl 
groups, present real promise for obtaining new biomaterials useful in cell immobilization, controlled 
drug delivery and tissue engineering [29,30]. Tailored alginate hydrogels have been studied to 
transplant cells such as chondrocytes and osteoblasts and improve neo-cartilage or neo-bone formation. 
The beneficial use of these modified alginate gels as biomaterials has been demonstrated in a number 
of in vitro and in vivo studies [31]. 
3.3. Fucoidans 
3.3.1. From Marine Echinoderms 
Biological properties of sulfated fucoidans (or fucans) extracted from marine invertebrates such as 
sea urchins or sea cucumbers have been extensively studied. These polymers of L-fucose are 
homogeneous and unbranched and bear no substituent other than sulfate. As described for mammalian 
GAGs, they present anticoagulant and antithrombotic activities. They can act as a ligand for either  
L- or P-selectins like heparin or heparan sulfate. They also are active on cell growth, migration and 
adhesion [3]. 
3.3.2. From Seaweeds 
Fucoidans can also be isolated from Phaeophyceae cell wall; algal sulfated fucoidans are more 
complex than fucoidans found in marine invertebrates. Algal fucoidans are composed of fucosyl 
disaccharide repeating units substituted by sulfates or uronic acids; they present other substituents such 
as O-acetyl, and branches adding considerably to their heterogeneity (Figure 2) [32–34]. Mar. Drugs 2011, 9  
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Figure 2. Structure of sulfated oligofucoidan constitutive of algal fucoidan from 
Ascophyllum nodosum [32]. 
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After depolymerization (by acidic hydrolysis or free radical process), low-molecular-weight 
fractions of fucoidans (LMW fucans, <30 kDa) have been obtained and shown to exhibit   
some heparin-like properties, with less side effects. Heparin is a sulfated polysaccharide from porcine 
origin used as an antithrombotic drug; however, its antithrombotic efficacy is limited by its strong 
anticoagulant properties correlated with a high hemorrhagic risk. The venous antithrombotic activity of 
LMW fucans (LMWF) has been compared with a low-molecular-weight heparin in the Wessler rabbit 
model and exhibited a better ratio antithrombotic effect/hemorrhagic risk [35–37]. Moreover   
LMWF exhibited arterial antithrombotic activity in vivo as well. Indeed, LMWF injections improved 
residual muscle blood flow and increased vessel formation in acute hind limb ischemia model in rat; 
they prevented arterial thrombosis induced by apoptosis in rabbit with no increase of bleeding risk 
(Figure 3) [38,39]. This antithrombotic activity may, in part, be explained by the decrease of tissue 
factor expression in the media of denuded arteries and the significant increase of plasma TFPI 
(inhibitor of the extrinsic coagulation pathway) released from endothelial cell by fucoidan as 
previously shown in vitro [39,40]. 
These results led us to further study sulfated polysaccharide-endothelial cell interaction. Owing to 
their ionic structure, LMWF, like heparin, can bind and modulate the activity of proangiogenic growth 
factors such as fibroblast growth factors (FGF) [41,42]. Fucoidan enhanced in vitro tube formation by 
mature endothelial cells in the presence of FGF-2 [43]. This effect correlated with a decrease of PAI-1 
(plasminogen activator inhibitor) release, and an upregulation of the cell-surface α6 integrin subunit, 
which could explain the proangiogenic activity [42–44]. Mar. Drugs 2011, 9  
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Figure 3. Angiographies of hind limbs from rabbits, 3 days after apoptosis induction.   
(a) Rabbit receiving LMWF; (b) Rabbit receiving placebo. 
 
(a) (b) 
Until recently, vessel formation was claimed to be related to in situ mature endothelial cell 
proliferation, migration and differentiation. In 1997, Asahara and Isner demonstrated the presence   
of endothelial progenitor cells (EPCs) in circulating blood, which play a major role in vasculogenesis 
in physiological and pathological situations when organ vascularization, and regeneration, is   
required [45]. Autologous infusion of EPCs would potentially be a promising therapy for 
revascularizing ischemic tissues. Unfortunately these EPCs are very rare in blood. Moreover further 
evidence indicates that not only the cell number but also functional properties of transplanted EPCs 
determine the outcome of autologous stem cell transplantation. The poor graft efficiency seems to be 
related to unfavorable functional changes during the expansion procedure. We demonstrated that 
fucoidan induced EPCs to adopt a proangiogenic phenotype. It enhanced their proliferation, migration 
and differentiation into capillary-like structures on Matrigel [46]. LMWF could act through SDF-1, 
which when stimulated during EPCs expansion increased their therapeutic potential after cell 
transplantation in a model of hind limb ischemia [47,48]. 
LMWF has demonstrated some anti-inflammatory properties such as anti-complementary activities 
with both inhibition of leukocyte margination and connective tissue proteolysis. LMWF could be used 
for treating some inflammatory diseases in which uncontrolled extracellular matrix degradation takes 
place [49]. As described above, LMWF can also promote tissue rebuilding parameters such as 
signaling by heparin-binding growth factors (FGF-2, VEGF) and collagen processing in fibroblasts, 
smooth muscle cells or endothelial cells in culture. Recently, a study showed that LMWF can bind 
fibrillar collagens and provide protection and signal promotion of heparin binding growth factors to 
improve biocompatibility of purified cancellous bone substitute. Indeed, it was demonstrated that 
LMWF mimicks and restores the properties of bone non collagenous matrix (proteoglycans, 
glycoproteins) that were eliminated by drastic purification process during design of the biomaterial, to 
regulate soluble factors bioavailability [50]. Mar. Drugs 2011, 9  
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4. GAG-Like Polysaccharides from Marine Prokaryotes 
4.1. Extracellular Polymeric Substances (EPS)-Producing Cyanobacteria 
Cyanobacteria (blue-green algae) are Gram-negative photosynthetic prokaryotes considered as a 
rich source of novel molecules of a great importance from a biotechnological and industrial   
point of view. Many cyanobacteria produce extracellular polymeric substances (EPS) mainly of 
polysaccharidic nature. These EPS can remain associated to the cell surface as sheaths, capsules and/or 
slimes, or be liberated into the surrounding environment as released polysaccharides [51]. 
4.2. Spirulina (Arthrospira) 
Spirulina is a microalga which offers a broad range of applications such as a nutritive or 
pharmaceutical additive with no risk to health. Clinical studies suggest that compounds in the 
microalgae have therapeutic functions and especially polysaccharides with antiflammatory effects [52]. 
Spirulan, existing as a ionic form (calcium or sodium), is a sulfated polysaccharide isolated from 
Arthrospira platensis (formely Spirulina platensis) and consisting of two types of disaccharide 
repeating units, [→3)-α-L-Rha(1→2)-α-L-Aco-(1→] where Aco (acofriose) is 3-O-methyl-Rha with 
sulfate groups and O-hexuronosyl-rhamnose. It also contains trace amounts of xylose, glucuronic acid 
and galacturonic acid. Its molecular weight is about 200 × 10
3 g/mol and it bears from 5 to 20% sulfate 
depending on the source [53]. Spirulan is reported to inhibit pulmonary metastasis in humans and to 
prevent the adhesion and proliferation of tumor cells. Highly porous scaffolds have been constructed 
by electrospining biomass of Spirulina. In these conditions, well defined nanofibers were produced to 
be used as extracellular matrices for stem cell culture and future treatment of spinal cord injury [54]. 
Other EPS-Producing Cyanobacteria 
Cyanobacteria of the genera Aphanocapsa, Cyanothece, Gloeothece, Synechocystis, Phormidium, 
Anabaena and Nostoc are able to produce sulfated polysaccharides containing uronic acids. 
Applications of cyanobacterial polysaccharides have been poorly investigated in the biomedical field 
except as antiviral agents. Moreover, the overall negative charge of cyanobacterial EPS may be 
essential for sequestering metal cations that are essential for cell growth but present at low 
concentrations in their surroundings, and/or preventing the direct contact between the cells and toxic 
heavy metals dispersed in the environment [55]. 
4.3. Bacterial Exopolysaccharides (EPS) 
Marine biosphere offers wealthy flora and fauna living in different unusual ecosystems embracing 
diverse microbial communities: deep-sea hydrothermal vents, Arctic and Antartic sea-ice, 
Mediterranean shallow vents, microbial mats located in some polynesian atolls [56–63]. 
Deep-sea microorganisms, bacteria and archaea, or the processes they mediate in situ, and the 
promise of their primary and secondary products present a great interest to biotechnology and a 
potential for pharmaceutical applications [64–66]. From different oceanographic cruises organised to 
explore deep-sea hydrothermal vent environments (East Pacific Rise, North Fiji, Guaymas basin and Mar. Drugs 2011, 9  
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Mid Atlantic Ridge), several polysaccharide-producing bacteria have been discovered. Screenings 
have been performed mainly on mesophilic bacteria rather than on psychrophilic, thermophilic or 
hyperthermophilic strains. Up to date, three main genera of polysaccharide-producing bacteria have 
been identified: Pseudoalteromonas  sp.,  Alteromonas sp. and Vibrio sp. By fermentation, each 
bacterium can liberate into the culture medium (an aerobic carbohydrate-based medium) one specific 
polysaccharide with an original structure and with an interesting yield, from 0.5 g to 4 g of 
polysaccharide/liter of culture broth [59].  
4.3.1. HE 800 EPS from Vibrio diabolicus 
The  Vibrio diabolicus bacterium was isolated from a Pompei worm tube (polychaete Alvinella 
pompejana); the EPS it secreted was characterized by equal amounts of glucuronic acid and 
hexosamine (N-acetyl glucosamine and N-acetyl galactosamine). It is a hyaluronic acid-like polymer 
(Figure 4) [67,68] and its commercial name is Hyalurift
®. 
Figure 4. Repeating unit of the marine bacterial polysaccharide (HE800 EPS) produced by 
Vibrio diabolicus [68]. 
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The efficiency of this high-molecular-weight (>10
6 g/mol) linear polysaccharide was evaluated on 
the restoration of bone integrity for critical size defects (CSD) performed on the calvaria of Wistar 
male rats. Collagen was used as a control. Briefly, bacterially produced polysaccharide or collagen  
(as control) was put into a hole made in the right parietal bone while another hole made in the left 
parietal bone was kept free of any compound. In the presence of EPS secreted by Vibrio diabolicus, 
bone healing was almost complete after 15 days; the anatomy of the defect with trabecular and cortical 
structure was totally restored. Neovascularization was also observed along with an organized 
trabecular bone. No abnormal bone growth or conjunctival abnormalities were noticed. Conversely, the 
collagen-treated animals did not demonstrate significant healing [69]. 
These results could be explained by the HE800 EPS effects observed subsequently in in vitro 
models of tissue remodeling. Indeed, it was demonstrated that HE800 EPS enhanced collagen 
structuring in engineering connective tissue model and promoted fibroblast settled in extracellular 
matrix. Using the capability of acido-soluble collagen I to auto-associate into fibrils after pH 
neutralizing, a reconstructed extracellular matrix containing human fibroblasts was produced and 
studied by electron microscopy and classical histology. By electron microscopy, it was observed that 
addition of HE800 EPS, during collagenous matrix building, increased and accelerated collagen fibrils 
formation with 67 nm periodic striations. 
Study on fibroblasts distribution in different parts of reconstructed connective tissues demonstrated 
the ability of HE800 EPS to modulate signals mediated by cell-matrix interactions. In this in vitro Mar. Drugs 2011, 9  
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model, proliferating cells were preferentially located at the tissue surface. In order to distinguish 
between fibroblasts colonizing the extracellular matrix and fibroblasts living and proliferating at the 
surface of the reconstructed tissue, stained histological sections were studied by image analysis. 
Observations showed that in reconstructed tissue containing HE800 EPS, cells at the periphery 
proliferated and massively migrated in the extracellular matrix. We could conclude that this EPS 
specifically improved cytocompatibility of the engineered tissue. Therefore, the use of HE800 EPS to 
design collagenic engineered tissue for skin or cartilage grafting can be suggested [70]. These efforts 
to design innovative medical devices or tissue engineering products demonstrate that HE800 EPS in 
native form could find application in the future as a new biomaterial for tissue therapy. 
With the purpose of preparing a GAG-like compound, this high-molecular-weight EPS was first 
depolymerized by a free-radical reaction. Then the newly depolymerized EPS was chemically sulfated 
with pyridine-sulfur trioxyde in dimethylformamide. These chemical modifications can yield a low 
molecular weight (<20 kDa) and sulfated polysaccharide with new properties. In fact, 
depolymerization, N-deacetylation and sulfation produced a HE800 EPS derivative, referred to as DRS 
HE800, which is structurally close to heparan-sulfate. It was also demonstrated that other EPS having 
no GAG structural features could be modified in order to acquire heparan sulfate properties. The effect 
of this HE800 EPS derivative was tested in proliferation assays. Thus, in two-dimensional culture this 
derivative was capable of stimulating the proliferation of dermal and gingival fibroblasts. And 
moreover, this derivative could inhibit the secretion of matrix metalloproteinases (MMPs) such as 
gelatinase A (MMP-2) and stromelysin 1 (MMP-3) by fibroblasts after IL-1β induction [71]. 
Vascularization in tissue engineering is a challenge; indeed tissue repair is possible only in the 
presence of new vessels contributing to tissue growth. New vessels, contributing to vascular and tissue 
repair, are formed by two different processes. The first involves proliferation and migration of in situ 
mature endothelial cells. In the second process, the new vessels of proliferating, migrating, and 
differentiating endothelial progenitor cells (EPCs) from the bone marrow, are incorporated under the 
influence of proangiogenic factors such as VEGF. In vitro studies showed that DRS HE800 exhibited 
no proangiogenic properties (proliferation, migration, differentiation tested by vascular tube formation 
on Matrigel) either on mature endothelial cells such as HUVEC (human umbilical vein endothelial 
cells), or on EPCs [72] (Figure 5). 
Figure 5. Effect of the DRS HE800 derivative on vascular tube formation on Matrigel 
from endothelial progenitor cells (EPCs). Photographs show vascular tube formation by 
EPCs previously treated (a) with 5% of fetal calf serum (control); (b) with proangiogenic 
factor VEGF (40 ng/mL); and (c) with proangiogenic factor VEGF (40 ng/mL) and DRS 
HE800 derivative (10 µg/mL). 
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4.3.2. EPS GY 785 from Alteromonas infernus 
A bacterium named Alteromonas infernus was isolated from a sample of fluid collected among a 
dense population of Riftia pachyptila. The EPS it secretes is a highly branched acidic 
heteropolysaccharide with a high molecular weight (>1.5 × 10
6 g/mol) and a low sulfate content 
(≤10%). Its nonasaccharide repeating unit is composed of uronic acid (galacturonic and   
glucuronic acid) and neutral sugars (galactose and glucose) and substituted with one sulfate group  
(Figure 6) [73,74]. 
Figure 6. Repeating unit of marine bacterial polysaccharide (GY785 EPS) produced by 
Alteromonas infernus [74,75]. 
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A very recent study demonstrated that the high molecular weight GY785 EPS associated with an 
injectable silylated hydroxypropylmethylcellulose-based hydrogel (Si-HPMC) could significantly 
improve the mechanical properties of this new hydrogel construct. The attachment of chondrocytes and 
osteoblasts was induced when the cells were cultivated in two-dimensional culture on the top of the 
hydrogel containing 0.67% of GY785 EPS. In three-dimensional culture, GY785 EPS increased 
viability and proliferation of the chondrocytes. The hydrogel supplemented with 0.67% GY785 EPS 
presented an interesting feature for cartilage tissue engineering applications [76]. 
As described above, with the aim of promoting biological activities, preparations of GY785 
derivatives have been undertaken to obtain oversulfated low molecular weight polysaccharides. These 
derivatives demonstrated a weak anticoagulant activity compared to heparin (10 times less). Two types 
of derivatives (SDR and DRS) were obtained according to the process used. A process with a first step 
of sulfation (S) and a subsequent second step of free radical depolymerization (DR) gave the SDR 
derivatives. A process with a first step of free-radical depolymerization (DR) and a subsequent second 
step of sulfation (S) resulted in DRS derivatives. Surprisingly, the two types of derivatives did not 
present the same biological properties. The addition of SDR derivative in the culture medium 
containing FGF-2 increased the proliferation of mature endothelial cells, whereas the DRS derivative 
had no effect. In the in vitro angiogenesis assay, performed to observe the differentiation of mature 
endothelial cells into vascular tubes on Matrigel, pre-treatment of cells with SDR derivative increased 
significantly the formation of vascular tubes, whereas DRS derivatives did not have the same effect. In 
conclusion SDR GY785 EPS derivative has pro-angiogenic effect contrary to DRS GY785 EPS 
derivative [77]. However, in the same experimental conditions, SDR GY785 EPS derivative had no Mar. Drugs 2011, 9  
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effect on proliferation, migration and vascular tube formation on Matrigel from endothelial progenitor 
cells [72]. In summary, SDR GY785 EPS derivative exhibits pro-angiogenic effect contrary to DRS 
GY785 EPS derivative, but only in the presence of mature endothelial cells. 
In other models of study, it was demonstrated that DRS GY785 EPS stimulated some human 
mesenchymal cells: dermal fibroblasts, gingival fibroblasts, stromal medullar cells. In two-dimensional 
cultures, this EPS derivative promoted FGF-2 signaling, and thus cell proliferation. This effect was 
also observed when cells were associated with extracellular collagenous matrix. Furthermore, DRS 
GY785 EPS derivatives were able to inhibit some processes involved in tissue breakdown and 
inflammation such as complement cascade, and induction of MMPs by inflammatory cytokines such as 
IL-1β and TNF-α [71]. Recently, the effect of this derivative on osteogenesis was investigated because 
it was previously described that the growth and differentiation of bone cells is controlled by several 
factors, which can be modulated by heparan sulfates [78]. It was shown that this DRS GY785 EPS 
derivative inhibited osteoclastogenesis. In addition, the DRS GY785 EPS derivative reduced 
proliferation and accelerated osteoblastic differentiation, leading to strong inhibition of mineralised 
nodule formation, which would be in favor of an increase of bone resorption. Taken together, these 
data show different levels of bone resorption regulation by the DRS GY785 EPS derivative, leading to 
proresorptive effects [79]. 
5. Conclusions 
Marine organisms offer a great diversity of polysaccharides showing interesting biological 
properties mimicking those described for the mammalian GAGs. Among the different sources of 
polysaccharides, algal polysaccharides such as fucoidans and especially their LMW derivatives could 
play an important role in future development of cell therapy and regenerative medicine. Bacterial 
polysaccharides present also a real potential in cell therapy and tissue engineering with an advantage 
over the polysaccharides from eukaryotes, since they can be produced totally under controlled 
conditions in bioreactors. As described for other polysaccharides, some derivatives can be obtained by 
chemical modifications, to optimize the biological properties and design drugs with improved benefit 
and low risk for the patient. 
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